CLAIMS:

1. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2
2. A serum albumin binding antibody or fragment thereof comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4
3. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 and a light chain variable domain having the sequence given in SEQ ID NO:3
4. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain domain having the sequence given in SEQ ID NO: 2and a light chain variable domain having the sequence given SEQ ID NO:4.
5. A serum albumin binding antibody or fragment according to any one of claims 1 to 4, where the antibody or fragment is selected from the group consisting of a Fab, modified Fab, Fab', F(ab')2, Fv, single variable domain antibody, scFv, bi, tri or tetra-valent antibody, Bis-scFv, diabody, triabody, tribody, DVD-Ig and BiTE.
6. A bispecific antibody fusion protein comprising:

   a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (VH1), a CH1 domain and a second heavy chain variable domain (VH2),

   a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (VL1), a CL domain and a second light chain variable domain (VL2),

   wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site,

   wherein the antigen bound by the second antigen binding site is human serum albumin and wherein the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:1 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 3, and

   the second heavy chain variable domain (VH2) and second light chain variable domain (VL2) are optionally linked by a disulphide bond.
7. A bispecific antibody fusion protein comprising:

a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (VH1), a CH1 domain and a second heavy chain variable domain (VH2),

a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (VL1), a CL domain and a second light chain variable domain (VL2),

wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site,

wherein the antigen bound by the second antigen binding site is human serum albumin,

wherein the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:2 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 4 and

the second heavy chain variable domain (VH2) and second light chain variable domain (VL2) are optionally linked by a disulphide bond.

8. A polynucleotide encoding an antibody or fragment as defined in any one of claims 1 to 7.

9. A vector comprising a polynucleotide as defined in claim 8.

10. A host cell comprising a polynucleotide of claim 8 or a vector according to claim 9.

11. A process of producing an antibody or fragment defined in any one of claims 1 to 7 comprising expressing same from a host cell as defined in claim 10.

12. A pharmaceutical formulation comprising an antibody or fragment as defined in any one of claims 1 to 7.

13. Use of an antibody or fragment as defined in any one of claims 1 to 7, in the manufacture of a medicament.

14. An antibody or fragment according to any one of claims 1 to 7, for use in treatment.

CLAIMS:

1. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 and a light chain variable domain having the sequence given in SEQ ID NO:3

2. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 2 and a light chain variable domain having the sequence given SEQ ID NO:4.

3. A serum albumin binding antibody or fragment according to any one of claims 1 to 2, where the antibody or fragment is selected from the group consisting of a Fab, modified Fab, Fab', F(ab')2, Fv, single variable domain antibody, scFv, bi, tri or tetra-valent antibody, Bis-scFv, diabody, triabody, tribody, DVD-Ig and BiTE.

4. A bispecific antibody fusion protein comprising:

a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (VH1), a CH1 domain and a second heavy chain variable domain (VH2),

a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (VL1), a CL domain and a second light chain variable domain (VL2),

wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site,

wherein the antigen bound by the second antigen binding site is human serum albumin and wherein the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:1 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 3, and

the second heavy chain variable domain (VH2) and second light chain variable domain (VL2) are optionally linked by a disulphide bond.

5. A bispecific antibody fusion protein comprising:

a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (VH1), a CH1 domain and a second heavy chain variable domain (VH2),

a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (VL1), a CL domain and a second light chain variable domain (VL2),

wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site,

wherein the antigen bound by the second antigen binding site is human serum albumin,

wherein the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:2 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 4 and

the second heavy chain variable domain (VH2) and second light chain variable domain (VL2) are optionally linked by a disulphide bond.

6. A polynucleotide encoding an antibody or fragment as defined in any one of claims 1 to 5.
7. A vector comprising a polynucleotide as defined in claim 6.
8. A host cell comprising a polynucleotide of claim 6 or a vector according to claim 7.
9. A process of producing an antibody or fragment defined in any one of claims 1 to 5 comprising expressing same from a host cell as defined in claim 8.
10. A pharmaceutical formulation comprising an antibody or fragment as defined in any one of claims 1 to 5.
11. Use of an antibody or fragment as defined in any one of claims 1 to 5, in the manufacture of a medicament.
12. An antibody or fragment according to any one of claims 1 to 5, for use in treatment.